Hotta Mari, Ohwada Rina, Akamizu Takashi, Shibasaki Tamotsu, Kangawa Kenji
Health Services Center, National Graduate Institute for Policy Studies, Tokyo, Japan.
Methods Enzymol. 2012;514:381-98. doi: 10.1016/B978-0-12-381272-8.00024-6.
Anorexia nervosa (AN) is an eating disorder characterized by a decrease in caloric intake and malnutrition. It is associated with a variety of medical morbidities as well as significant mortality. Nutritional support is of paramount importance to prevent impaired quality of life later in life in affected patients. Some patients with restricting-type AN who are fully motivated to gain body weight cannot increase their food intake because of malnutrition-induced gastrointestinal dysfunction. Chronicity of AN prevents participation in social activities and leads to increased medical expenses. Therefore, there is a pressing need for effective appetite-stimulating therapies for patients with AN. Ghrelin is the only orexigenic hormone that can be given intravenously. Intravenous infusion of ghrelin is reported to increase food intake and body weight in healthy subjects as well as in patients with poor nutritional status. Here, we introduce the results of a pilot study that investigated the effects of ghrelin on appetite, energy intake, and nutritional parameters in five patients with restricting-type AN, who are fully motivated to gain body weight but could not increase their food intake because of malnutrition-induced gastrointestinal dysfunction.
神经性厌食症(AN)是一种以热量摄入减少和营养不良为特征的饮食失调症。它与多种医学疾病以及显著的死亡率相关。营养支持对于预防受影响患者日后生活质量受损至关重要。一些限制型AN患者虽有充分的增重意愿,但由于营养不良导致的胃肠功能障碍,无法增加食物摄入量。AN的慢性病程会妨碍患者参与社交活动,并导致医疗费用增加。因此,迫切需要为AN患者提供有效的促食欲疗法。胃饥饿素是唯一可静脉注射的促食欲激素。据报道,静脉输注胃饥饿素可增加健康受试者以及营养状况较差患者的食物摄入量和体重。在此,我们介绍一项试点研究的结果,该研究调查了胃饥饿素对五名限制型AN患者食欲、能量摄入和营养参数的影响,这些患者虽有充分的增重意愿,但因营养不良导致的胃肠功能障碍而无法增加食物摄入量。